GTB 5550
Alternative Names: B7H3 TriKE™; cam1615B7H3; camB7-H3 TriKE®; Camelid Nanobody B7-H3 Tri-Specific Killer Engager - GT Biopharma; GTB-5550; GTB-5550 TriKE™Latest Information Update: 22 May 2026
At a glance
- Originator University of Minnesota
- Developer GT Biopharma
- Class Antineoplastics; Immunoglobulin fragments; Immunoglobulin Fv fragments; Immunotherapies; Interleukins; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 replacements; Natural killer cell stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Multiple myeloma
Most Recent Events
- 08 Apr 2026 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (SC) (NCT07541573)
- 03 Feb 2026 GT Biopharma plans a phase I dose escalation basket trial trial for GBT 5550 in Solid tumours in mid-2026
- 03 Feb 2026 The US FDA approves IND application for GTB 5550 in Solid tumours